Management Of Cardiovascular Disease In Women

Cardiovascular disease is the leading cause of death in women in the US, with more women dying from heart disease than men. Women may have different presentation from men and often need a different approach to diagnosis and treatment. There are also unique topics of management of heart disease in women, including issues during pregnancy, lactation, and menopause. Many different health care providers, as well as cardiologists are involved in treating these patients. A manual reviewing diagnosis and treatment of cardiac disease in women would help providers without specific cardiology training to deliver care with greater efficiency. A practical and comprehensive guide geared towards these providers would be a highly practical and valuable resource that would be utilized in everyday practice in offices that include urban clinics, general medicine offices, obstetrics and gynecology offices, as well as in the surgical subspecialties. This book will be a highly practical resource that can be directly applied to the issues that arise in everyday practice. There is no available book on the market that focuses on a broader approach to cardiac disease in women or focuses on non-cardiology providers (and their trainees) who have the need to know more about treatment of cardiovascular disease in women.​

This book reviews all aspects of the diagnosis and management of heart disease in women, covering areas such as gender differences in metabolic syndrome, hypertension and atherogenesis. Gender differences in cardiovascular diseases are widespread, but while gender medicine takes into account the effects of sex and gender on the health of women and men, traditionally, women have been underrepresented in cardiovascular clinical trials, in management of different cardiac diseases and drug use. Gender Differences in the Pathogenesis and Management of Heart Disease deals with the gender-specific differences in cardiac physiology and diseases and brings into perspective the critical significance of gender in management of cardiovascular disease presentations and management. As such it is of enormous use to all clinical staff who manage women with cardiovascular disease.

Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data--including population surveys, cohort studies, disease registries, administrative health data, and vital statistics--contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.

Pathophysiology of Cardiovascular Disease has been divided into four sections that focus on heart dysfunction and its associated characteristics (hypertrophy, cardiomyopathy and failure); vascular dysfunction and disease; ischemic heart disease; and novel therapeutic interventions. This volume is a compendium of different approaches to understanding cardiovascular disease and identifying the proteins, pathways and processes that impact it.

Cardiovascular disease (CVD), once thought to be confined primarily to industrialized nations, has emerged as a major health threat in developing countries. Cardiovascular disease now accounts for nearly 30 percent of deaths in low and middle income countries each year, and is accompanied by significant economic repercussions. Yet most governments, global health institutions, and development agencies have largely overlooked CVD as they have invested in health in developing countries. Recognizing the gap between the compelling evidence of the global CVD burden and the investment needed to prevent and control CVD, the National Heart, Lung, and Blood Institute (NHLBI) turned to the IOM for advice on how to catalyze change. In this report, the IOM recommends that the NHLBI, development agencies, nongovernmental organizations, and governments work toward two essential goals: creating environments that promote heart healthy lifestyle choices and help reduce the risk of chronic diseases, and building public health infrastructure and health systems with the capacity to implement programs that will effectively detect and reduce risk and manage CVD. To meet these goals, the IOM recommends several steps, including improving cooperation and collaboration; implementing effective and feasible strategies; and informing efforts through research and health surveillance. Without better efforts to promote cardiovascular health, global health as a whole will be undermined.

Cardiovascular disease (CVD) is the largest single cause of death among women, accounting for one third of all deaths. In the United States, more women than men die every year of CVD. In the United States, 38.2 million women (34%) are living with CVD, and the population at risk is even larger. Cardiovascular Disease in Women Essentials is a current, concise, and authoritative guide to the diagnosis, treatment and management of cardiovascular disease in women. This pocket-size, quick reference is an ideal resource for primary care physicians, cardiologists, internal medicine physicians, and physicians in training.

Despite media attention and public awareness, recent advances in pharmaceutical and medical developments, heart disease in women is under-diagnosed, under-treated, and under-managed. Many women fail to present in the clinic when symptomatic, because of responsibilities at home or at work. Often the first presentation follows a cardiac event. Women are excluded from many clinical trials regardless of age or cardiac history, simply because most trials are aimed at male patients. This best-selling, updated title, aimed at changing this treatment of women's cardiac issues, covers all aspects of female cardiovascular disease. It is required reading for all practitioners who assess female patients.

Take advantage of new insights into prevention, diagnosis and treatment of coronary heart disease in women -- to the benefit of your patients. Designed to optimize your daily practice, this book gives lucid, up-to-date answers to numerous questions: What are the risks and benefits of hormone replacement therapy? What are the major risk factors for coronary heart disease in women? What are the most appropriate diagnostic tests in women? Which is the better treatment option for the woman with myocardial infarction -- lysis or primary angioplasty?